GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Accrelist Ltd (SGX:QZG) » Definitions » EV-to-EBITDA

Accrelist (SGX:QZG) EV-to-EBITDA : -5.47 (As of May. 31, 2025)


View and export this data going back to 2002. Start your Free Trial

What is Accrelist EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Accrelist's enterprise value is S$14.88 Mil. Accrelist's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was S$-2.72 Mil. Therefore, Accrelist's EV-to-EBITDA for today is -5.47.

The historical rank and industry rank for Accrelist's EV-to-EBITDA or its related term are showing as below:

SGX:QZG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.56   Med: -0.58   Max: 60.61
Current: -5.47

During the past 13 years, the highest EV-to-EBITDA of Accrelist was 60.61. The lowest was -6.56. And the median was -0.58.

SGX:QZG's EV-to-EBITDA is ranked worse than
100% of 500 companies
in the Healthcare Providers & Services industry
Industry Median: 12.075 vs SGX:QZG: -5.47

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-31), Accrelist's stock price is S$0.035. Accrelist's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was S$-0.016. Therefore, Accrelist's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Accrelist EV-to-EBITDA Historical Data

The historical data trend for Accrelist's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accrelist EV-to-EBITDA Chart

Accrelist Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.62 4.09 -4.41 9.69 -6.06

Accrelist Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 9.69 - -6.06 -

Competitive Comparison of Accrelist's EV-to-EBITDA

For the Medical Care Facilities subindustry, Accrelist's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accrelist's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Accrelist's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Accrelist's EV-to-EBITDA falls into.


;
;

Accrelist EV-to-EBITDA Calculation

Accrelist's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=14.878/-2.718
=-5.47

Accrelist's current Enterprise Value is S$14.88 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Accrelist's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was S$-2.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accrelist  (SGX:QZG) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Accrelist's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.035/-0.016
=At Loss

Accrelist's share price for today is S$0.035.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Accrelist's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was S$-0.016.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Accrelist EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Accrelist's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Accrelist Business Description

Traded in Other Exchanges
N/A
Address
10 Ubi Crescent, Ubi Techpark, Lobby E No. 03-95, Singapore, SGP, 408564
Accrelist Ltd is focused on the distribution of electronics components, plastic injection molding, mold design, and fabrication services. The company's segment comprises a Mechanical business unit (MBU), Aesthetic Medical Services (AMS), and others. Accrelist is focused on maintaining a diversified customer mix and product portfolio for MBU and EBU while continuing to expand upon the medical aesthetic products and services provided to consumers. it generates a vast majority of revenue from the MBU segment.

Accrelist Headlines

No Headlines